
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: I'm interested!!!
Zacks Equity Research
Shares of
Annovis Bio, Inc.(ANVS) have gained 0.1% over the past four weeks to close the last trading session at $7.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets,
the mean estimate of $33.50 indicates a potential upside of 359.5%.
The average comprises four short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $26.26. While the lowest estimate indicates an increase of 78.3% from the current price level, the most optimistic estimate points to an 887.7% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
However, an impressive consensus price target is not the only factor that indicates a potential upside in ANVS.
This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
Price, Consensus and EPS Surprise
Zacks Price, Consensus and EPS Surprise Chart for ANVS
Here's Why There Could be Plenty of Upside Left in ANVS
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 26.6%, as two estimates have moved higher compared to no negative revision.
GBA BUY TODAY!!!!